AC44C6CF Southern Norfolk Rebuild NS Scale N Set 8520 Decals

  1. Home
  2. AC44C6CF Southern Norfolk Rebuild NS Scale N Set 8520
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Norfolk Southern AC44C6CF Rebuild 8520 Set N Scale NS
Condition: New: A brand-new, unused, unopened, undamaged item (including handmade items). See the seller's Brand:

Circus City Decals




Clear Waterslide Decals

Material: Waterslide Decal Country/Region of Manufacture: USA
Recommended Age Range: 8-99 Gender: Boys & Girls
Year: 2020 Grading: Brand New

Does not apply

published on tue nov 09 2021

AC44C6CF Southern Norfolk Rebuild NS Scale N Set 8520 Decals

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

AC44C6CF Southern Norfolk Rebuild NS Scale N Set 8520 Decals

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.